Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 613950 | 12 pages | https://doi.org/10.1155/2013/613950

Gallic Acid Induces a Reactive Oxygen Species-Provoked c-Jun NH2-Terminal Kinase-Dependent Apoptosis in Lung Fibroblasts

Academic Editor: Byung-Cheul Shin
Received20 Aug 2012
Revised21 Dec 2012
Accepted25 Dec 2012
Published20 Feb 2013


Idiopathic pulmonary fibrosis is a chronic lung disorder characterized by fibroblasts proliferation and extracellular matrix accumulation. Induction of fibroblast apoptosis therefore plays a crucial role in the resolution of this disease. Gallic acid (3,4,5-trihydroxybenzoic acid), a common botanic phenolic compound, has been reported to induce apoptosis in tumor cell lines and renal fibroblasts. The present study was undertaken to examine the role of mitogen-activated protein kinases (MAPKs) in lung fibroblasts apoptosis induced by gallic acid. We found that treatment with gallic acid resulted in activation of c-Jun NH2-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and protein kinase B (PKB, Akt), but not p38MAPK, in mouse lung fibroblasts. Inhibition of JNK using pharmacologic inhibitor (SP600125) and genetic knockdown (JNK specific siRNA) significantly inhibited p53 accumulation, reduced PUMA and Fas expression, and abolished apoptosis induced by gallic acid. Moreover, treatment with antioxidants (vitamin C, N-acetyl cysteine, and catalase) effectively diminished gallic acid-induced hydrogen peroxide production, JNK and p53 activation, and cell death. These observations imply that gallic acid-mediated hydrogen peroxide formation acts as an initiator of JNK signaling pathways, leading to p53 activation and apoptosis in mouse lung fibroblasts.

1. Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive and usually fatal disorder with a reported median survival of 3 to 6 years from the time of diagnosis [1]. Clinically, IPF is characterized by the loss of lung epithelium and the formation of scar tissue within the lungs with accumulation of fibroblasts and myofibroblasts that deposit excessive extracellular matrix including collagen [2]. Increasing evidence shows that the abnormal wound repair process in response to alveolar epithelial injury is responsible for IPF and fibroblast-to-myofibroblast differentiation, which represents a key event during tissue repair [2]. The origin of pathological fibroblasts foci within the IPF lesion remains puzzling. Possibilities include differentiation of resident fibroblasts, recruitment of circulating fibroblast precursors, and transdifferentiation of epithelial cells into pathological fibroblast phenotypes [3, 4]. Apoptosis plays an important role in both normal lung homeostasis and lung remodeling associated with fibrotic lung disease. In IPF, widespread epithelial apoptosis is observed. In contrast to epithelial cells, fibroblasts derived from IPF lungs are more resistant to apoptosis than normal lung fibroblasts [5]. Whether apoptosis promotes or inhibits the pathogenesis of pulmonary fibrosis depends upon the cell type involved and the microenvironment of the affected lung. Immoderate cell loss in the alveolar epithelium may be important early in IPF progression, while reduced fibroblasts/myofibroblasts apoptosis has been associated with the formation of fibrotic lesions [6]. As such, novel therapies based on the stimulation of apoptosis of activated fibroblasts may prove beneficial to the treatment of patients with IPF.

Gallic acid (3,4,5-trihydroxybenzoic acid), a natural botanic phenolic compound, is widely distributed in green tea, red wine, and grapes, and so forth. Preclinical studies have shown that gallic acid possesses a variety of pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, and anticancer activities [79]. Recently, gallic acid has been found to exert potent antiviral effect at the therapeutic range of 0.8–0.05  g/mL [10]. In animal models, gallic acid reduces oxidative stress and enhances the levels of glutathione (GSH), GSH peroxidase, GSH reductase, and GSH S-transferase in hepatic tissue, as well as catalase in serum [11]. It also can inhibit the saturation of odd-chain polyunsaturated fatty acid [12] and has antiangiogenesis activities [13]. Exposure of human stomach cancer KATO III cells and human colon adenocarcinoma COLO 205 cells to gallic acid led to both growth inhibition and induction of apoptosis [14]. Hsu et al. reported that gallic acid induces apoptosis in preadipocyte cells via a Fas- and mitochondrial-mediated pathway [15]. Our previous report demonstrated that gallic acid induces apoptosis of mouse lung fibroblasts via a reactive-oxygen-species-(ROS-) dependent ataxia-telangiectasia-mutated-(ATM-) p53 activation pathway [16]. It is well known that excessive levels of intracellular ROS not only directly damage cells by oxidizing DNA, protein, and lipid, but also indirectly damage cells by activating a variety of stress-sensitive intracellular signaling pathways such as p38MAPK and JNK [17, 18]. Therefore, in this study, we attempted to address whether gallic acid-mediated ROS production can activate JNK and lead to apoptosis in mouse lung fibroblasts.

2. Material and Methods

2.1. Chemicals

Gallic acid, ascorbic acid (ASC), N-acetylcysteine (NAC), LY294002, SP600125, and KU55933 were purchased from Sigma (St. Louis, MO, USA). Anti-p53 (Cat. no. 2524), anti-phospho- (Cat. no. 9275S), anti-phospho- (Cat. no. 4060S), anti-JNK (Cat. no. 9258), anti-phospho-JNK (Cat. no. 9251) antibodies, and U0126 were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Anti-PUMA (Cat. no. ab9643) and anti-phospho-ATM ( ) kinase (Cat. no. ab78-100) antibodies were procured from Abcam (Cambridge, UK). Anti-Fas (Cat. no. sc-74540), anti-phospho-ERK (Cat. no. sc-7383), anti-phospho-p38 (Cat. no. sc-7937), and anti- -actin (Cat. no. sc-47778) antibodies were purchased from Santa Cruz Biotechnology, Inc. Terminal deoxynucleotidyl transferase-mediated dUTP-fluorescein nick end-labeling (TUNEL) assay kit was purchased from Roche Diagnostics (Mannheim, Germany). JNK-specific siRNA was obtained from Applied Biosystems (Foster City, CA).

2.2. Mouse Lung Fibroblast Isolation and Culture

ICR mice aged 8–10 weeks were dissected under asphyxia. The lungs and upper airway were removed and placed into 10 cm Petri dishes containing HSBB buffer. After rinsing twice with HBSS buffer, the tissues were minced into 1–3 mm pieces and incubated with trypsin, collagenase, and DNase. The samples were filtered, and equivalent medium was added to discontinue decomposition. After centrifugation, cells were harvested and cultured in DMEM-10% FBS supplemented with 1% L-glutamine, 1% nonessential amino acid, penicillin (100 units/mL), and streptomycin (100  g/mL). The viability of isolated lung fibroblasts was approximately 75%. All experiments were performed with primary mouse lung fibroblasts at 3 to 15 passages. Average plating efficiency was >95%.

2.3. Western Blot Analysis

Cells were lysed at 4°C in RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, 5 mM EDTA (pH 8.0), and 1 mM EGTA, and supplemented with protease and phosphatase inhibitors. After 20 min of lysis on ice, cell debris was removed by microcentrifugation, followed by quick freezing of the supernatants. The protein concentration was determined by the Bradford method. Equal amounts of total protein were separated onto SDS-polyacrylamide gels and then electrophoretically transferred from the gel onto a PVDF membrane (Millipore, Bedford, MA). Membranes were blocked for 1 h in phosphate-buffered saline (PBS) containing 0.1% Tween-20 and 10% non-fat dry milk (NFDM). After blocking, the membrane was reacted with specific primary antibodies against p- (1 : 1000), p- (1 : 1000), p-ERK (1 : 1500), p-JNK (1 : 1000), JNK (1 : 1000), p-p38MAPK (1 : 1000), p-ATM (1 : 1000), p53 (1 : 1000), PUMA (1 : 1000), Fas (1 : 1000), and -actin (1 : 2000), overnight at 4°C. Following extensive washings with PBS/T (5 changes over 30 min), membranes were incubated with HRP-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies (1 : 10,000) (PerkinElmer, Inc., Boston, MA) for 1 h. The blots were visualized using an ECL-Plus detection kit (PerkinElmer Life Sciences, Inc. Boston, MA, USA).

2.4. Apoptotic Cell Determination

After treatment, cells were fixed with 2% paraformaldehyde for 20 min and washed twice with PBS. Then, the cells were permeabilized with 0.1% Trion-X 100 for 30 min and incubated in a TUNEL reaction buffer for 2 h. TUNEL assay protocol was carried out according to the manufacturer’s instructions. After reaction with the TUNEL buffer, cells were incubated with DAPI for 10 min, and the images were visualized using a fluorescence microscope. TUNEL-positive cells were counted as apoptotic cells by flow cytometry.

2.5. Measurement of Reactive-Oxygen-Species-(ROS) Generation

Dihydroethidine (DCF-DA) is a specific superoxide tracing dye, which is frequently used to monitor H2O2 and hydroxyl radical levels in cells. To detect the levels of intracellular ROS production, cells were incubated for the indicated times in the absence or presence of gallic acid and then treated with 5  M dihydroethidine or 5  M H2DCF-DA (Molecular Probes, Eugene, OR, USA) for 30 min prior to harvesting. After rinsing twice with PBS, cells were detached, and fluorescence was measured with a FACS Calibur flow cytometer using Cell Quest software.

2.6. siRNA Transfection

To knockdown JNK expression, synthetic JNK siRNA duplex oligomer and a scrambled siRNA duplex oligomer were purchased from Applied Biosystems. For siRNA transfection experiments, mouse lung fibroblasts were plated onto 60 mm dishes ( per dish) and cultured overnight in complete medium. The following morning, cells were transiently transfected with Oligofectamine (Invitrogen) supplemented with JNK siRNA (30 and 50 nM) for 16 h. The levels of specific protein were detected by immunoblotting by treating with gallic acid for indicated times. The apoptotic cells were measured after 24 h gallic acid administration.

2.7. Statistical Analysis

All the figures shown in this paper were obtained from at least three independent experiments with similar results. All data are presented as mean SD of at least three separate experiments. Statistical differences were evaluated using the Student's t-test and considered significant at * , ** , or *** .

3. Results

3.1. Involvement of JNK Activation in Gallic Acid-Mediated Apoptosis

Our previous studies showed that the ROS-mediated ATM/p53 signaling plays a critical role in gallic acid-induced cell death in primary cultured mouse lung fibroblasts. It was found that the inhibition of ATM/p53 activity by pharmacologic and genetic strategies partially blocked the gallic acid-induced apoptotic process [16], indicating that another pathway might also be involved in gallic acid-triggered lung fibroblast apoptosis. It has also been reported that mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB/Akt) signaling pathways are the primary intermediates for the induction of apoptosis by oxidative stress [19]. Our recent report demonstrated that gallic acid-induced ROS generation and apoptotic cell death is in a time- and dose-dependent manner [16]. Thus, the time and dose effect of gallic acid on the activity of MAPKs and Akt in mouse lung fibroblasts was examined by immunoblot analysis using antibodies against phosphorylated form of MAPKs and Akt. In this study, we found that gallic acid exerts time- and dose-dependent effects in levels of phosphorylated JNK, ERK, and Akt in lung fibroblasts (Figures 1(a) and 1(b)). However, no visible p38MAPK phosphorylation was observed. The total amounts of ERK, JNK, p38MAPK, and Akt were not affected by gallic acid (data not shown).

To address the potential role of Akt, ERK, and JNK phosphorylation in gallic acid-induced apoptosis, mouse lung fibroblasts were exposed to gallic acid in the presence of specific inhibitors of Akt, ERK, and JNK (LY294002, U0126, and SP600125, respectively). The percentage of gallic acid-induced apoptotic cells was then determined by TUNEL assay at 24 h. As shown in Figure 1(c), gallic acid-induced apoptosis was significantly inhibited by pretreatment of SP600125. In contrast, pretreatment with LY294002 and U0126 accelerated gallic acid-mediated apoptosis in mouse lung fibroblasts. These results revealed that activation of JNK is mostly involved in gallic acid-induced apoptotic cell death. However, activation of ERK and Akt may protect mouse lung fibroblasts against gallic acid-mediated cell death.

3.2. JNK Activation Contributes to Gallic Acid-Elicited p53 Activation, Fas and PUMA Expression, and Apoptosis Induction

JNK has been shown to activate p53 in response to different stressful stimuli, and such phosphorylation can initiate p53 response, leading to cell cycle arrest and apoptosis [20]. To examine whether JNK activation plays a role in gallic acid-induced p53 accumulation and downstream apoptotic events, mouse lung fibroblasts were pretreated with SP600125 (0.1, 0.5, and 1  M) for 1 h prior to gallic acid incubation. The levels of p53, PUMA, and Fas were determined by Western blotting. Consistent with the results of previous studies, exposure to gallic acid significantly increased the levels of p53 (Figure 2(a)); however, pretreatment with JNK inhibitor SP600125 dose dependently reduced p53 levels. Similarly, gallic acid-mediated increase of proapoptotic proteins, PUMA and Fas protein levels, was also attenuated by pretreatment with SP600125 (Figure 2(b)).

To further confirm the role of JNK in gallic acid-triggered p53 accumulation, Fas and PUMA expression, and to avoid nonspecific effects of SP600125, knockdown of JNK expression by JNK-specific siRNA in mouse lung fibroblasts was carried out. As expected, the level of JNK was suppressed by JNK siRNA in a dose-dependent manner (Figure 3(a)). Gallic acid-induced Fas and PUMA upregulation (Figure 3(b)) and cytotoxicity (demonstrated by decrease in TUNEL-positive cells) were also diminished in JNK-siRNA-treated mouse lung fibroblasts, compared with control-siRNA treated culture (Figure 3(c)). These results indicated that JNK plays an upstream role in the gallic acid-induced p53 activation and apoptotic signaling pathway.

3.3. Gallic Acid-Provoked ROS Generation Is Required for JNK Activation and Downstream Apoptotic Process

To examine whether JNK signaling pathway is also required for gallic acid response through ROS production, mouse lung fibroblasts were exposed to gallic acid in the absence or presence of antioxidants, N-acetylcysteine (NAC), and ascorbic acid (ASC). The levels of phosphorylated JNK, p53, PUMA, and Fas were determined by Western blot. As expected, antioxidants (both ASC and NAC) significantly abolished the gallic acid-induced JNK and p53 activation as well as PUMA and Fas upregulation (Figure 4(a)), suggesting that ROS induced by gallic acid plays a crucial role in JNK phosphorylation and proapoptotic protein expression in lung fibroblasts. Our previous report suggested that the relative level of hydrogen peroxide was elevated at 30 min after gallic acid treatment [16]. To obtain further insight into the effects of catalase, an antioxidative enzyme, on the gallic acid-mediated hydrogen peroxide production and apoptotic process, mouse lung fibroblasts were preincubated with catalase for 1 h and then treated with gallic acid for another 30 min (for ROS generation assay) or 24 h (for apoptosis determination). As shown in Figure 4(b), the addition of catalase completely inhibited hydrogen peroxide formation of mouse lung fibroblasts. Moreover, catalase treatment effectively inhibited the phosphorylation of ATM and JNK. This event was accompanied by decreased expression of p53, PUMA, and Fas (Figure 4(c)), as well as mouse lung fibroblast apoptosis (Figure 4(d)). These data revealed that gallic acid-mediated hydrogen peroxide formation acts as an upstream regulator of ATM, JNK, and p53 activation and Fas and PUMA upregulation, to exert its apoptotic influence in mouse lung fibroblasts.

3.4. Synergistic Effect of ATM and JNK on Gallic Acid-Induced Mouse Lung Fibroblasts Apoptosis

Based on other’s and our studies, both ATM and JNK are upstream regulators of p53 phosphorylated activation [16, 21]. To characterize the interplay between ATM and JNK during gallic acid-mediated apoptotic process, mouse lung fibroblasts cells were treated with ATM kinase inhibitor KU-55933 and/or JNK inhibitor SP600125 prior to addition of gallic acid. As shown in Figure 5, pretreatment of KU-55933 or SP600125 alone only partially diminished gallic acid-mediated cytotoxicity, as demonstrated by a decrease in TUNEL-positive cells. However, a treatment with both KU-55933 and SP600125 displayed a synergistic protection of mouse lung fibroblasts against gallic acid-elicited apoptosis. To explore the interplay between ATM and JNK in gallic acid-induced apoptosis, the effect of ATM inhibitor on the JNK phosphorylation was examined. As shown in Figure 5(b), pretreatment of ATM inhibitor KU-55933 did not affect gallic acid-induced phosphorylation of JNK. Next, the influence of JNK inhibition on ATM phosphorylated activation was also investigated. As indicated in Figure 5(c), inhibition of JNK activity by SP600125 could alter the levels of phosphorylated ATM induced by gallic acid (Figure 5(c)). Our data suggested that ATM and JNK contribute to two different pathways with synergistic effect on gallic acid-triggered mouse lung fibroblast apoptosis.

4. Discussion

Idiopathic pulmonary fibrosis is a progressive interstitial lung disorder with no effective therapies. There is growing evidence demonstrating that the activation of pulmonary fibroblast is a key issue in the pathogenesis of lung fibrosis. Therefore, recent antifibrotic treatment has focused on the inhibition of lung fibroblasts activation and its related subsequent events, such as extracellular matrix deposition and enhanced proliferation [22]. Antioxidative agents are useful in both the prevention of lung injury and the attenuation of fibrogenesis, and many agents exhibit their antifibrotic effects through this mechanism [23]. Gallic acid is a natural phenolic compound with strong antioxidative activity [24]. Our previous study showed that gallic acid induces apoptosis in mouse lung fibroblasts. Treatment with gallic acid activates ROS-mediated DNA damage signaling pathway by triggering ATM-dependent activation of p53. The transcriptional activation of p53 upregulates the proapoptotic molecules, such as PUMA and Fas, and provokes caspase activation via both intrinsic and extrinsic pathways, consequently leading to apoptotic cell death [16]. However, treatment with ATM inhibitor cannot completely block gallic acid-induced p53 activation and cell death, suggesting that another pathway may be involved in p53 activation and subsequent gallic acid-mediated cytotoxic effect. In this study, we aimed to examine new insights into the other possible mechanisms of gallic acid-induced apoptosis in mouse lung fibroblasts. Our observations showed that JNK activation also contributes to gallic acid-elicited p53 activation and apoptosis induction. Gallic acid-mediated increases of proapoptotic proteins, PUMA and Fas protein levels, are attenuated by pharmacological and genetic inhibition (JNK inhibitor SP600125 and JNK-specific siRNA) of JNK. Moreover, a treatment with both ATM and JNK inhibitor (KU-55933 and SP600125, respectively) displays a synergistic protection of mouse lung fibroblasts against gallic acid-elicited apoptosis. These findings reveal that JNK-dependent p53 activation is another pathway involved in gallic acid-induced apoptosis.

Gallic acid, commonly distributed in various plants, fruits, and foods [24], has anticancer activity and induces apoptotic cell death in various types of cancer cells, such as prostate [25], lung [26, 27], gastric, colon, breast, cervical, and esophageal [28]. There is increasing evidence suggesting that apoptosis induced by gallic acid is associated with oxidative stress derived from reactive-oxygen-species-(ROS), mitochondrial dysfunction, and an increase in intracellular Ca2+ level [2931]. Inoue et al. reported that the intracellular peroxide level induced by gallic acid in HL-60RG cells was well correlated with the potency to induce apoptosis, and that the increased intracellular peroxides after gallic acid treatment seemed likely to have resulted from the influx of H2O2, which was generated extracellularly [32]. Similarly, we found that pretreatment with catalase completely inhibited gallic acid-triggered hydrogen peroxide accumulation and apoptotic death in lung fibroblasts (Figures 4(b) and 4(c)). Moreover, pretreatment with antioxidants, ascorbic acid, and NAC, as well as catalase significantly attenuated gallic acid-elicited ATM, JNK, and p53 activation, and subsequently increased PUMA and Fas protein levels (Figures 4(a) and 4(d)). These results suggested that hydrogen peroxide induced by gallic acid acts as an upstream signal that stimulates the activation of both ATM and JNK and then induces a p53-dependent apoptosis in lung fibroblasts.

In cells, numerous stress response signaling molecules are rapidly activated in response to oxidative insults. Some of these molecules are preferentially linked to enhanced survival, while others are more frequently associated with cell death. Mitogen-activated protein kinases (MAPKs), including extracellular signal regulated kinase (ERK1/2), c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and p38MAPK, are involved in cell proliferation and differentiation and cell death [33]. There is growing evidence indicating that ROS can stimulate the activation of ERK [34, 35], JNK, and p38MAPK [3638]. In most instances, ERK activation has a prosurvival function, rather than proapoptotic effects [39]. Several studies demonstrate that ERK activation serves as a survival factor following oxidant injury; inhibition of ERK activation sensitizes cells to hydrogen peroxide [40]. Consistent with this study, exposure to gallic acid increased the levels of phosphorylated ERK (p-ERK) (Figure 1(a)). Treatment with ERK inhibitors (U0126) accelerated gallic acid-mediated apoptosis in mouse lung fibroblasts (Figure 1(b)), suggesting that activation of ERK might act as a prosurvival factor in this event. Akt, known as protein kinase B, is a serine/threonine kinase which is activated via a phosphoinositide 3-kinase (PI3K) pathway [41]. Like ERK, Akt is also an important antiapoptotic prosurvival kinase during the cellular response to oxidant injury [42]. Sonoda et al. reported that administration of cells with wortmannin blocked hydrogen peroxide-induced Akt activation and increased cell death [43]. Using a genetic approach to elevate Akt expression directly supports the evidence that Akt plays an important role in enhancing cell survival following oxidant injury in hydrogen peroxide-treated HeLa and NIH3T3 cells [44]. In the results of this study, we also found that activation of Akt was accompanied by gallic acid-provoked ROS generation; however, treatment with LY294002 to inactivate Akt significantly accelerated gallic acid-induced cell death. These results suggest that activation of ERK and Akt is possibly increased as a result of intracellular ROS stress that further induces anti-apoptotic signaling to protect cell against oxidative injury upon gallic acid treatment.

The JNK and p38MAPK pathways are noted for their activation by a wide range of stresses including cytokines, radiation, osmotic shock, mechanical injury, heat stress, and oxidative damage [45]. In general, the activation of JNK and p38MAPK by ROS leads to apoptosis in various types of cells [3638]. The JNK inhibitor could protect rat pheochromocytoma PC12 cells against gallic acid-triggered cell death [46], while the p38MAPK inhibitor was found to decrease the death induced by pyrogallol in calf pulmonary artery endothelial cells [47]. Here, we provide evidence that ROS-mediated JNK activation, but not p38MAPK, is an early regulator in response to gallic acid treatment, which occurs concomitantly with the onset of apoptosis. Treatment with the chemical JNK inhibitor SP600125 and JNK-specific siRNA significantly attenuated apoptosis following gallic acid treatment (Figures 1(b), 2, and 3), suggesting that the ROS-induced JNK activation plays an important role in the apoptosis of mouse lung fibroblasts. However, Park reported that both JNK and p38 inhibitors did not affect cell death, ROS, and GSH levels in the gallic acid-treated human pulmonary fibroblast cells [48]. It is possible that the anti- or proapoptotic effects of the MAPKs by ROS on gallic acid-treated cells may vary depending on cell type and treated conditions.

The tumor suppressor protein p53 constitutes a potential target of proapoptotic signaling by JNK and exerts a proapoptotic influence in response to oxidative stress. It has been reported that p-JNK physically interacts with p53 and stabilizes it by phosphorylation at residue threonine 81. The phosphorylation of p53 at threonine 81 is required for the dissociation of p53 from Ubc13, leading to p53 accumulation, multimerization, and transcriptional activation [49]. Stress and damage stimuli-triggered apoptosis has been shown to be induced through activation of p53 via JNK signaling in HRas MCF10A cells [50], Lewis lung carcinoma (LLC) cells, hepatoma HepG2 cells, and Molt-4 leukemia cells [51]. Silibinin, a mixture of flavonolignans, induces p53-mediated cell death via ROS-mediated JNK activated pathways in human cervical carcinoma HeLa cells [52] and in human fibrosarcoma HT1080 cells [53]. Our current study showed that ROS-mediated JNK activation was accompanied by p53 activation. Pharmacological and genetic inhibition of JNK by SP600125 and JNK-specific siRNA effectively abolished p53 accumulation and PUMA/Fas expression, indicating that gallic acid-induced apoptosis occurs via ROS-JNK-p53-PUMA/Fas signaling pathway.

In conclusion, our previous studies revealed that ROS-mediated ATM activation is an upstream regulator of p53 activation in gallic acid-induced cell death in mouse lung fibroblasts [16]. Here, we provide evidence that ROS-induced JNK activation is an initiator that mediates p53 accumulation and activation and the subsequent increase of proapoptotic protein PUMA and Fas expression. Based on our previous study, as well as the present study, it is apparent that gallic acid most likely exerts its antifibrotic effects directly through the ROS-JNK/ATM-p53 signaling pathways, utilizing both mitochondria (PUMA) and death receptor (Fas) as the effectors of cell death (Figure 6). Gallic acid has been studied in vivo exhibiting antiproliferative, proapoptotic, and antitumorigenic effects in xenograft animal models [25, 54, 55]. Furthermore, gallic acid treatment has been also shown to induce apoptosis of rheumatoid arthritis fibroblast-like synoviocytes isolated from patients [56]. Our data provide the molecular mechanisms of gallic acid in the fight against lung fibroblasts in an in vitro model. However, the in vivo animal model study should be performed for further evaluating the possible application of this compound in the prevention and perhaps in therapy for pulmonary fibrosis.


  1. J. A. Bjoraker, J. H. Ryu, M. K. Edwin et al., “Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 1, pp. 199–203, 1998. View at: Google Scholar
  2. B. Hinz, “Formation and function of the myofibroblast during tissue repair,” Journal of Investigative Dermatology, vol. 127, no. 3, pp. 526–537, 2007. View at: Publisher Site | Google Scholar
  3. R. J. Phillips, M. D. Burdick, K. Hong et al., “Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis,” Journal of Clinical Investigation, vol. 114, no. 3, pp. 438–446, 2004. View at: Publisher Site | Google Scholar
  4. B. C. Willis, J. M. Liebler, K. Luby-Phelps et al., “Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis,” American Journal of Pathology, vol. 166, no. 5, pp. 1321–1332, 2005. View at: Google Scholar
  5. F. Drakopanagiotakis, A. Xifteri, V. Polychronopoulos, and D. Bouros, “Apoptosis in lung injury and fibrosis,” European Respiratory Journal, vol. 32, no. 6, pp. 1631–1638, 2008. View at: Publisher Site | Google Scholar
  6. C. L. Fattman, “Apoptosis in pulmonary fibrosis: too much or not enough?” Antioxidants and Redox Signaling, vol. 10, no. 2, pp. 379–385, 2008. View at: Publisher Site | Google Scholar
  7. A. Abdelwahed, I. Bouhlel, I. Skandrani et al., “Study of antimutagenic and antioxidant activities of Gallic acid and 1,2,3,4,6-pentagalloylglucose from Pistacia lentiscus. Confirmation by microarray expression profiling,” Chemico-Biological Interactions, vol. 165, no. 1, pp. 1–13, 2007. View at: Publisher Site | Google Scholar
  8. K. K. Sohi, N. Mittal, M. K. Hundal, and K. L. Khanduja, “Gallic acid, an antioxidant, exhibits antiapoptotic potential in normal human lymphocytes: a Bcl-2 independent mechanism,” Journal of Nutritional Science and Vitaminology, vol. 49, no. 4, pp. 221–227, 2003. View at: Google Scholar
  9. Y. J. Kim, “Antimelanogenic and antioxidant properties of gallic acid,” Biological and Pharmaceutical Bulletin, vol. 30, no. 6, pp. 1052–1055, 2007. View at: Publisher Site | Google Scholar
  10. B. Ozcelik, M. Kartal, and I. Orhan, “Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids,” Pharmaceutical Biology, vol. 49, no. 4, pp. 396–402, 2011. View at: Publisher Site | Google Scholar
  11. C. L. Hsu and G. C. Yen, “Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats,” British Journal of Nutrition, vol. 98, no. 4, pp. 727–735, 2007. View at: Publisher Site | Google Scholar
  12. N. Nakano, N. Shirasaka, H. Koyama et al., “C19 odd-chain polyunsaturated fatty acids (PUFAs) are metabolized to C21-PUFAs in a rat liver cell line, and curcumin, gallic acid, and their related compounds inhibit their desaturation,” Bioscience, Biotechnology and Biochemistry, vol. 64, no. 8, pp. 1641–1650, 2000. View at: Google Scholar
  13. Z. Liu, J. Schwimer, D. Liu et al., “Gallic acid is partially responsible for the antiangiogenic activities of Rubus leaf extract,” Phytotherapy Research, vol. 20, no. 9, pp. 806–813, 2006. View at: Publisher Site | Google Scholar
  14. K. Yoshioka, T. Kataoka, T. Hayashi, M. Hasegawa, Y. Ishi, and H. Hibasami, “Induction of apoptosis by gallic acid in human stomach cancer KATO III and colon adenocarcinoma COLO 205 cell lines,” Oncology Reports, vol. 7, no. 6, pp. 1221–1223, 2000. View at: Google Scholar
  15. C. L. Hsu, W. H. Lo, and G. C. Yen, “Gallic acid induces apoptosis in 3T3-L1 pre-adipocytes via a fas- and mitochondrial-mediated pathway,” Journal of Agricultural and Food Chemistry, vol. 55, no. 18, pp. 7359–7365, 2007. View at: Publisher Site | Google Scholar
  16. C. Y. Chuang, H. C. Liu, L. C. Wu, C. Y. Chen, J. T. Chang, and S. L. Hsu, “Gallic acid induces apoptosis of lung fibroblasts via a reactive oxygen species-dependent ataxia telangiectasia mutated-p53 activation pathway,” Journal of Agricultural and Food Chemistry, vol. 58, no. 5, pp. 2943–2951, 2010. View at: Publisher Site | Google Scholar
  17. J. E. Klaunig, L. M. Kamendulis, and B. A. Hocevar, “Oxidative stress and oxidative damage in carcinogenesis,” Toxicologic Pathology, vol. 38, no. 1, pp. 96–109, 2010. View at: Publisher Site | Google Scholar
  18. H. Yuan, X. Zhang, X. Huang et al., “NADPH oxidase 2-derived reactive oxygen species mediate FFAs-Induced dysfunction and apoptosis of b- Cells via JNK, p38 MAPK and p53 pathways,” PLoS ONE, vol. 5, no. 12, Article ID e15726, 2010. View at: Publisher Site | Google Scholar
  19. S. Ueda, H. Masutani, H. Nakamura, T. Tanaka, M. Ueno, and J. Yodoi, “Redox control of cell death,” Antioxidants and Redox Signaling, vol. 4, no. 3, pp. 405–414, 2002. View at: Google Scholar
  20. S. W. Gen, “The functional interactions between the p53 and MAPK signaling pathways,” Cancer Biology and Therapy, vol. 3, no. 2, pp. 156–161, 2004. View at: Google Scholar
  21. K. Kobayashi and I. Tsukamoto, “Prolonged Jun N-terminal kinase (JNK) activation and the upregulation of p53 and p21WAF1/CIP1 preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin,” Biochimica et Biophysica Acta, vol. 1537, no. 1, pp. 79–88, 2001. View at: Publisher Site | Google Scholar
  22. H. L. Hadden and C. A. Henke, “Induction of lung fibroblast apoptosis by soluble fibronectin peptides,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 4, pp. 1553–1560, 2000. View at: Google Scholar
  23. D. Zhang, C. Huang, C. Yang et al., “Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts,” Respiratory Research, vol. 12, p. 154, 2011. View at: Publisher Site | Google Scholar
  24. R. Niemetz and G. G. Gross, “Enzymology of gallotannin and ellagitannin biosynthesis,” Phytochemistry, vol. 66, no. 17, pp. 2001–2011, 2005. View at: Publisher Site | Google Scholar
  25. M. Kaur, B. Velmurugan, S. Rajamanickam, R. Agarwal, and C. Agarwal, “Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, pro-apoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice,” Pharmaceutical Research, vol. 26, no. 9, pp. 2133–2140, 2009. View at: Publisher Site | Google Scholar
  26. Y. Ohno, K. Fukuda, G. Takemura et al., “Induction of apoptosis by gallic acid in lung cancer cells,” Anti-Cancer Drugs, vol. 10, no. 9, pp. 845–851, 1999. View at: Google Scholar
  27. M. Kawada, Y. Ohno, Y. Ri et al., “Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice,” Anti-Cancer Drugs, vol. 12, no. 10, pp. 847–852, 2001. View at: Publisher Site | Google Scholar
  28. A. Faried, D. Kurnia, L. S. Faried et al., “Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines,” International Journal of Oncology, vol. 30, no. 3, pp. 605–613, 2007. View at: Google Scholar
  29. N. Sakaguchi, M. Inoue, and Y. Ogihara, “Reactive oxygen species and intracellular Ca2+, common signals for apoptosis induced by gallic acid,” Biochemical Pharmacology, vol. 55, no. 12, pp. 1973–1981, 1998. View at: Publisher Site | Google Scholar
  30. H. M. Chen, Y. C. Wu, Y. C. Chia et al., “Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate cancer cells,” Cancer Letters, vol. 286, no. 2, pp. 161–171, 2009. View at: Publisher Site | Google Scholar
  31. M. Inoue, R. Suzuki, T. Koide, N. Sakaguchi, Y. Ogihara, and Y. Yabu, “Antioxidant, gallic acid, induces apoptosis in HL-60RG cells,” Biochemical and Biophysical Research Communications, vol. 204, no. 2, pp. 898–904, 1994. View at: Publisher Site | Google Scholar
  32. M. Inoue, N. Sakaguchi, K. Isuzugawa, H. Tani, and Y. Ogihara, “Role of reactive oxygen species in gallic acid-induced apoptosis,” Biological and Pharmaceutical Bulletin, vol. 23, no. 10, pp. 1153–1157, 2000. View at: Google Scholar
  33. J. Blenis, “Signal transduction via the MAP kinases: proceed at your own RSK,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 5889–5892, 1993. View at: Google Scholar
  34. Y. Liu, G. L. Borchert, A. Surazynski, C. A. Hu, and J. M. Phang, “Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling,” Oncogene, vol. 25, no. 41, pp. 5640–5647, 2006. View at: Publisher Site | Google Scholar
  35. K. Z. Guyton, Y. Liu, M. Gorospe, Q. Xu, and N. J. Holbrook, “Activation of mitogen-activated protein kinase by H2O2: role in cell survival following oxidant injury,” Journal of Biological Chemistry, vol. 271, no. 8, pp. 4138–4142, 1996. View at: Google Scholar
  36. X. Mao, C. Rong Yu, W. Hua Li, and W. Xin Li, “Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells,” Cell Research, vol. 18, no. 8, pp. 879–888, 2008. View at: Publisher Site | Google Scholar
  37. Y. H. Hsin, C. F. Chen, S. Huang, T. S. Shih, P. S. Lai, and P. J. Chueh, “The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells,” Toxicology Letters, vol. 179, no. 3, pp. 130–139, 2008. View at: Publisher Site | Google Scholar
  38. M. Gomez-Lazaro, M. F. Galindo, R. M. Melero-Fernandez De Mera et al., “Reactive oxygen species and p38 mitogen-activated protein kinase activate bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate,” Molecular Pharmacology, vol. 71, no. 3, pp. 736–743, 2007. View at: Publisher Site | Google Scholar
  39. E. S. Henson and S. B. Gibson, “Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy,” Cellular Signalling, vol. 18, no. 12, pp. 2089–2097, 2006. View at: Publisher Site | Google Scholar
  40. K. Z. Guyton, Y. Liu, M. Gorospe, Q. Xu, and N. J. Holbrook, “Activation of mitogen-activated protein kinase by H2O2: role in cell survival following oxidant injury,” Journal of Biological Chemistry, vol. 271, no. 8, pp. 4138–4142, 1996. View at: Google Scholar
  41. A. Arcaro, M. Aubert, M. E. Espinosa del Hierro et al., “Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling,” Cellular Signalling, vol. 19, no. 5, pp. 1081–1092, 2007. View at: Publisher Site | Google Scholar
  42. J. L. Martindale and N. J. Holbrook, “Cellular response to oxidative stress: signaling for suicide and survival,” Journal of Cellular Physiology, vol. 192, no. 1, pp. 1–15, 2002. View at: Publisher Site | Google Scholar
  43. Y. Sonoda, S. Watanabe, Y. Matsumoto, E. Aizu-Yokota, and T. Kasahara, “FAK is the upstream signal protein of the phosphatidylinositol 3- kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line,” Journal of Biological Chemistry, vol. 274, no. 15, pp. 10566–10570, 1999. View at: Publisher Site | Google Scholar
  44. X. Wang, K. D. McCullough, T. F. Franke, and N. J. Holbrook, “Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival,” Journal of Biological Chemistry, vol. 275, no. 19, pp. 14624–14631, 2000. View at: Publisher Site | Google Scholar
  45. A. Sakaguchi, K. Matsumoto, and N. Hisamoto, “Roles of MAP kinase cascades in Caenorhabditis elegans,” Journal of Biochemistry, vol. 136, no. 1, pp. 7–11, 2004. View at: Publisher Site | Google Scholar
  46. M. K. Kang, N. J. Kang, Y. J. Jang, K. W. Lee, and H. J. Lee, “Gallic acid induces neuronal cell death through activation of c-Jun N-terminal kinase and downregulation of Bcl-2,” Annals of the New York Academy of Sciences, vol. 1171, pp. 514–520, 2009. View at: Publisher Site | Google Scholar
  47. Y. H. Han, H. J. Moon, B. R. You, S. Z. Kim, S. H. Kim, and W. H. Park, “JNK and p38 inhibitors increase and decrease apoptosis, respectively, in pyrogallol-treated calf pulmonary arterial endothelial cells,” International Journal of Molecular Medicine, vol. 24, no. 5, pp. 717–722, 2009. View at: Publisher Site | Google Scholar
  48. W. H. Park, “MAPK inhibitors differentially affect gallic acid-induced human pulmonary fibroblast cell growth inhibition,” Molecular Medicine Reports, vol. 4, no. 1, pp. 193–197, 2011. View at: Publisher Site | Google Scholar
  49. I. Topisirovic, G. J. Gutierrez, M. Chen, E. Appella, K. L. B. Borden, and Z. A. Ronai, “Control of p53 multimerization by Ubc13 is JNK-regulated,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 12676–12681, 2009. View at: Publisher Site | Google Scholar
  50. M. S. Kim, J. Y. Kwon, N. J. Kang, K. W. Lee, and H. J. Lee, “Phloretin induces apoptosis in H-Ras MCF10A human breast tumor cells through the activation of p53 via JNK and p38 mitogen-activated protein kinase signaling,” Annals of the New York Academy of Sciences, vol. 1171, pp. 479–483, 2009. View at: Publisher Site | Google Scholar
  51. K. B. Lee, K. R. Kim, T. L. Huh, and Y. M. Lee, “Proton induces apoptosis of hypoxic tumor cells by the p53-dependent and p38/JNK MAPK signaling pathways,” International Journal of Oncology, vol. 33, no. 6, pp. 1247–1256, 2008. View at: Publisher Site | Google Scholar
  52. S. Fan, M. Qi, Y. Yu et al., “P53 activation plays a crucial role in silibinin induced ROS generation via PUMA and JNK,” Free Radical Research, vol. 46, no. 3, pp. 310–319, 2012. View at: Publisher Site | Google Scholar
  53. W. J. Duan, Q. S. Li, M. Y. Xia, S. I. Tashiro, S. Onodera, and T. Ikejima, “Silibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways,” Biological and Pharmaceutical Bulletin, vol. 34, no. 1, pp. 47–53, 2011. View at: Publisher Site | Google Scholar
  54. J. I. Bin-Chuan, W. H. Hsu, J. S. Yang et al., “Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo,” Journal of Agricultural and Food Chemistry, vol. 57, no. 16, pp. 7596–7604, 2009. View at: Publisher Site | Google Scholar
  55. C. Z. Liang, X. Zhang, H. Li et al., “Gallic acid induces the apoptosis of human osteosarcoma cells in vitro and in vivo via the regulation of Mitogen-activated protein kinase pathways,” Cancer Biotherapy Radiopharmaceuticals, vol. 27, no. 10, pp. 701–710, 2012. View at: Publisher Site | Google Scholar
  56. C. H. Yoon, S. J. Chung, S. W. Lee et al., “Gallic acid, a natural polyphenolic acid, induces apoptosis and inhibits proinflammatory gene expressions in rheumatoid arthritis fibroblast-like synoviocytes,” Joint Bone Spine, 2012. View at: Publisher Site | Google Scholar

Copyright © 2013 Chiu-Yuan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2382 Views | 1178 Downloads | 14 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.